Ident. | Authors (with country if any) | Title |
---|
000014 |
Nicolas Morin [Canada] ; Vincent A. Jourdain ; Thérèse Di Paolo | Modeling dyskinesia in animal models of Parkinson disease : ANIMAL MODELS OF PARKINSON'S DISEASE |
000017 |
Damian M. Herz [Allemagne, Danemark] ; Hartwig R. Siebner [Danemark] ; Oliver J. Hulme [Danemark] ; Esther Florin [Allemagne, Canada] ; Mark S. Christensen [Danemark] ; Lars Timmermann [Allemagne] | Levodopa reinstates connectivity from prefrontal to premotor cortex during externally paced movement in Parkinson's disease |
000044 |
James B. Koprich [Canada] ; Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Keith Jarvie [Canada] ; Anthony E. Lang [Canada] ; Philip Seeman [Canada] ; Jonathan M. Brotchie [Canada] | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques |
000087 |
Jolyn N. A. D'Andrea [Canada] ; Angela M. Haffenden [Canada] ; Sarah Furtado [Canada] ; Oksana Suchowersky [Canada] ; Bradley G. Goodyear [Canada] | Degradation of stored movement representations in the parkinsonian brain and the impact of levodopa |
000095 |
Christopher Kobylecki [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni, Canada] | Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia |
000135 |
Lars Timmermann [Allemagne] ; Esther Florin [Allemagne, Canada] | Parkinson's disease and pathological oscillatory activity: Is the beta band the bad guy? - New lessons learned from low-frequency deep brain stimulation |
000140 |
Behzad Elahi [Canada] ; Nicolás Phielipp [Canada] ; Robert Chen [Canada] | N-Methyl-D-Aspartate Antagonists in Levodopa Induced Dyskinesia: A Meta- Analysis |
000149 |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Tayyeba Darr [Canada] ; Donna Pires [Canada] ; Lili-Naz Hazrati [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased Levels of 5-HT1A Receptor Binding in Ventral Visual Pathways in Parkinson's Disease |
000173 |
Golnasim Riahi [Canada] ; Marc Morissette [Canada] ; Daniel Levesque [Canada] ; Claude Rouillard [Canada] ; Pershia Samadi [Canada] ; Martin Parent [Canada] ; Thérèse Di Paolo [Canada] | Effect of chronic L-DOPA treatment on 5-HT1A receptors in parkinsonian monkey brain |
000184 |
Rena K. Mann [Canada] ; Roderick Edwards [Canada] ; JULIE ZHOU [Canada] ; Alison Fenney [Canada] ; Mandar Jog [Canada] ; Christian Duval [Canada] | Comparing movement patterns associated with Huntington's chorea and Parkinson's dyskinesia |
000202 |
Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; QIN LI [République populaire de Chine] ; Jonathan Brotchie [Canada] ; Erwan Bezard [République populaire de Chine, France] | A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale |
000203 |
C. Paquette [États-Unis] ; E. Franzen [États-Unis, Suède] ; G. M. Jones [Canada] ; F. B. Horak [États-Unis] | WALKING IN CIRCLES: NAVIGATION DEFICITS FROM PARKINSON'S DISEASE BUT NOT FROM CEREBELLAR ATAXIA |
000216 |
James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada] | The Selective Mu-Opioid Receptor Antagonist ADL5510 Reduces Levodopa-Induced Dyskinesia Without Affecting Antiparkinsonian Action in MPTP-Lesioned Macaque Model of Parkinson's Disease |
000218 |
Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Shen-Yang Lim [Malaisie] ; Bernard Ravina [États-Unis] ; Klaus Seppi [Autriche] ; Miguel Coelho [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal] | The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Motor Symptoms of Parkinson's Disease |
000228 |
Diego Santos-Garcia [Espagne] ; Mercedes Macias [Espagne] ; Miguel Llaneza [Espagne] ; M Nica Grande [Espagne] ; Raúl De La Fuente-Fernandez [Canada] | Serum Vitamin B12 and Folate Levels in Parkinson's Disease Patients Treated with Duodenal Levodopa Infusion |
000253 |
Olivier Rascol [France] ; Andres Lozano [Canada] ; Matthew Stern [États-Unis] ; Werner Poewe [Autriche] | Milestones in Parkinson's Disease Therapeutics |
000256 |
Bazoumana Ouattara [Canada] ; Laurent Gregoire [Canada] ; Marc Morissette [Canada] ; Fabrizio Gasparini [Suisse] ; Ivo Vranesic [Suisse] ; Graeme Bilbe [Suisse] ; Donald R. Johns [Suisse] ; Alex Rajput [Canada] ; Oleh. Hornykiewicz [Autriche] ; Ali H. Rajput [Canada] ; Baltazar Gomez-Mancilla [Suisse] ; Therese Di Paolo [Canada] | Metabotropic glutamate receptor type 5 in levodopa-induced motor complications |
000293 |
A. Q. Rana [Canada] ; J. Depradine [Canada] | Abdominal Pain: A Symptom of Levodopa End of Dose Wearing off in Parkinson's Disease |
000294 |
Daniela Berg [Allemagne] ; Jana Godau [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Karla Eggert [Allemagne] ; Ilona Csoti [Allemagne] ; Alexander Storch [Allemagne] ; Heiko Huber [Allemagne] ; Monica Morelli-Canelo [Allemagne] ; Maria Stamelou [Allemagne] ; Vincent Ries [Allemagne] ; Martin Wolz [Allemagne] ; Christine Schneider [Allemagne] ; Therese Di Paolo [Canada] ; Fabrizio Gasparini [Suisse] ; Sam Hariry [Suisse] ; Marc Vandemeulebroecke [Suisse] ; Walid Abi-Saab [Suisse] ; Katy Cooke [Royaume-Uni] ; Donald Johns [Suisse] ; Baltazar Gomez-Mancilla [Suisse] | AFQ056 Treatment of Levodopa-Induced Dyskinesias: Results of 2 Randomized Controlled Trials |
000302 |
Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada] | The α2 Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian Primates |
000308 |
Marc Morissette [Canada] ; Pershia Samadi [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Nancy Belanger [Canada] ; Thérèse Di Paolo [Canada] | Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys |
000322 |
Pierre-Luc Tremblay [Canada] ; Marc-Andre Bedard [Canada] ; Dominic Langlois [Canada] ; Pierre J. Blanchet [Canada] ; Martin Lemay [Canada] ; Maxime Parent [Canada] | Movement chunking during sequence learning is a dopamine-dependant process: a study conducted in Parkinson's disease |
000323 |
Daniella Rylander [Suède] ; Martin Parent [Canada] ; Sean S. O'Sullivan [Royaume-Uni] ; Sandra Dovero [France] ; Andrew J. Lees [Royaume-Uni] ; Erwan Bezard [France] ; Laurent Descarries [Canada] ; M. Angela Cenci [Suède] | Maladaptive Plasticity of Serotonin Axon Terminals in Levodopa-Induced Dyskinesia |
000327 |
Galit Kleiner-Fisman [Canada] ; Andres Lozano [Canada] ; Elena Moro [Canada] ; Yu-Yan Poon [Canada] ; Anthony E. Lang [Canada] | Long-Term Effect of Unilateral Pallidotomy on Levodopa-Induced Dyskinesia |
000328 |
Cory Toth [Canada] ; Kim Breithaupt [Canada] ; SHAOHUA GE [Canada] ; YANJUN DUAN [Canada] ; Joan M. Terris [Canada] ; Anita Thiessen [Canada] ; Samuel Wiebe [Canada] ; Douglas W. Zochodne [Canada] ; Oksana Suchowersky [Canada] | Levodopa, Methylmalonic Acid, and Neuropathy in Idiopathic Parkinson Disease |
000338 |
Rena K. Mann [Canada] ; Roderick Edwards [Canada] ; Julie Zhou [Canada] ; Mandar Jog [Canada] ; Christian Duval [Canada] | Intra- and inter-limb coherency during stance in non-dyskinetic and dyskinetic patients with Parkinson's disease |
000340 |
Fabrizio Stocchi [Italie] ; Olivier Rascol [France] ; Karl Kieburtz [États-Unis] ; Werner Poewe [Autriche] ; Joseph Jankovic [États-Unis] ; Eduardo Tolosa [Espagne] ; Paulo Barone [Italie] ; Anthony E. Lang [Canada] ; C. Warren Olanow [États-Unis] | Initiating Levodopa/Carbidopa Therapy With and Without Entacapone in Early Parkinson Disease: The STRIDE-PD Study |
000356 |
Janis M. Miyasaki [Canada] | Evidence-based initiation of dopaminergic therapy in Parkinson's disease |
000357 |
Ron Levy [Canada] ; Andres M. Lozano [Canada] ; Anthony E. Lang [Canada] ; Jonathan O. Dostrovsky [Canada] | Event-related desynchronization of motor cortical oscillations in patients with multiple system atrophy |
000360 |
Sarah C. Lidstone [Canada] ; Michael Schulzer [Canada] ; Katherine Dinelle [Canada] ; Edwin Mak [Canada] ; Vesna Sossi [Canada] ; Thomas J. Ruth [Canada] ; Raul De La Fuente-Fernandez [Canada] ; Anthony G. Phillips [Canada] ; A. Jon Stoessl [Canada] | Effects of Expectation on Placebo-Induced Dopamine Release in Parkinson Disease |
000361 |
Bazoumana Ouattara [Canada] ; Fabrizio Gasparini [Suisse] ; Marc Morissette [Canada] ; Laurent Gregoire [Canada] ; Pershia Samadi [Canada] ; Baltazar Gomez-Mancilla [Suisse] ; Thérèse Di Paolo [Canada] | Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys |
000362 |
Tom H. Johnston [Canada] ; Anne Van Der Meij [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Effect of Histamine H2 Receptor Antagonism on Levodopa-Induced Dyskinesia in the MPTP-Macaque Model of Parkinson's Disease |
000384 |
B. Ouattara [Canada] ; D. Hoyer [Suisse] ; L. Gregoire [Canada] ; M. Morissette [Canada] ; F. Gasparini [Suisse] ; B. Gomez-Mancilla [Suisse] ; T. Di Paolo [Canada] | CHANGES OF AMPA RECEPTORS IN MPTP MONKEYS WITH LEVODOPA-INDUCED DYSKINESIAS |
000393 |
André Bonnici [Canada] ; Carola-Ellen Ruiner [Canada] ; Lyne St-Laurent [Canada] ; David Hornstein [Canada] | An Interaction Between Levodopa and Enteral Nutrition Resulting in Neuroleptic Malignant-Like Syndrome and Prolonged ICU Stay |
000421 |
P. A. Guertin [Canada] ; C. Brochu [Canada] | Preliminary evidence of safety following administration of L-DOPA and buspirone in an incomplete monoplegic patient |
000446 |
I. A. Prescott [Canada] ; J. O. Dostrovsky [Canada] ; E. Moro [Canada] ; M. Hodaie [Canada] ; A. M. Lozano [Canada] ; W. D. Hutchison [Canada] | Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients |
000449 |
S. J. Palmer [Canada] ; L. Eigenraam [Canada] ; T. Hoque [Canada] ; R. G. Mccaig [Canada] ; A. Troiano [Canada] ; M. J. Mckeown [Canada] | LEVODOPA-SENSITIVE, DYNAMIC CHANGES IN EFFECTIVE CONNECTIVITY DURING SIMULTANEOUS MOVEMENTS IN PARKINSON'S DISEASE |
000475 |
Robert A. Hauser [États-Unis] ; Michel Panisset [Canada] ; Giovanni Abbruzzese [Italie] ; Linda Mancione [États-Unis] ; Nalina Dronamraju [États-Unis] ; Algirdas Kakarieka [Suisse] | Double-Blind Trial of Levodopa/Carbidopa/Entacapone Versus Levodopa/Carbidopa in Early Parkinson's Disease |
000478 |
Vesna Sossi [Canada] ; Katherine Dinelle [Canada] ; Geoffrey J. Topping [Canada] ; James E. Holden [États-Unis] ; Doris Doudet [Canada] ; Michael Schulzer [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada] ; Raul De La Fuente-Femandez [Canada] | Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's : an in vivo imaging study |
000499 |
Connie Marras [Canada] ; Anthony E. Lang [Canada] ; Shirley W. Eberly [États-Unis] ; David Oakes [États-Unis] ; Stanley Fahn [États-Unis] ; Steven R. Schwid [États-Unis] ; Christopher Hyson [Canada] ; Ira Shoulson [États-Unis] | A Comparison of Treatment Thresholds in Two Large Parkinson's Disease Clinical Trial Cohorts |
000500 |
Laurent Gregoire [Canada] ; Arash Rassoulpour [États-Unis] ; Paolo Guidetti [États-Unis] ; Pershia Samadi [Canada] ; Paul J. Bedard [Canada] ; Emanuela Izzo [Italie] ; Robert Schwarcz [États-Unis] ; Therese Di Paolo [Canada] | Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys |
000507 |
Naomi P. Visanji [Canada] ; Rob M. A. De Bie [Canada] ; Tom H. Johnston [Canada] ; Andrew C. Mccreary [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | The Nociceptin/Orphanin FQ (NOP) Receptor Antagonist J-113397 Enhances the Effects of Levodopa in the MPTP-Lesioned Nonhuman Primate Model of Parkinson's Disease |
000513 |
Jasper E. Visser [Pays-Bas, Suisse] ; John H. J. Allum [Suisse] ; Mark G. Carpenter [Suisse, Canada] ; Rianne A. Esselink [Pays-Bas] ; Johannes D. Speelman [Pays-Bas] ; George F. Borm [Pays-Bas] ; Bastiaan R. Bloem [Pays-Bas] | Subthalamic nucleus stimulation and levodopa-resistant postural instability in Parkinson's disease |
000514 |
Anthony P. Nicholas [États-Unis] ; Farah D. Lubin [États-Unis] ; Penelope J. Hallett [États-Unis] ; Padmapriya Vattem [États-Unis] ; Paula Ravenscroft [Royaume-Uni] ; Erwan Bezard [France] ; SHAOBO ZHOU [Royaume-Uni] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] ; J. David Sweatt [États-Unis] ; David G. Standaert [États-Unis] | Striatal histone modifications in models of levodopa-induced dyskinesia |
000517 |
F. Paquet [Canada] ; M. A. Bedard [Canada] ; M. Levesque [Canada] ; P. L. Tremblay [Canada] ; M. Lemay [Canada] ; P. J. Blanchet [Canada] ; P. Scherzer [Canada] ; S. Chouinard [Canada] ; J. Filion [Canada] | Sensorimotor adaptation in Parkinson's disease : evidence for a dopamine dependent remapping disturbance |
000523 |
Anne Beuter [France] ; Roberto Hernandez [Canada] ; Robert Rigal [Canada] ; Julien Modolo [France] ; Pierre J. Blanchet [Canada] | Postural Sway and Effect of Levodopa in Early Parkinson's Disease |
000527 |
Cory Toth [Canada] ; Martin Sutton Brown [Canada] ; Sarah Furtado [Canada] ; Oksana Suchowersky [Canada] ; Douglas Zochodne [Canada] | Neuropathy as a Potential Complication of Levodopa Use in Parkinson's Disease |
000535 |
Susan H. Fox [Canada] ; Anthony E. Lang [Canada] | Levodopa-Related Motor Complications-Phenomenology |
000584 |
Sarah Lemieux [Canada] ; Mehrdad Ghassemi [Canada] ; Mandar Jog [Canada] ; Roderick Edwards [Canada] ; Christian Duval [Canada] | The influence of levodopa-induced dyskinesias on manual tracking in patients with Parkinson's disease |
000592 |
Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada] | Ten-Year Follow-Up of Parkinson's Disease Patients Randomized to Initial Therapy with Ropinirole or Levodopa |
000635 |
Panida Piboolnurak [Canada, Thaïlande] ; Anthony E. Lang [Canada] ; Andres M. Lozano [Canada] ; Janis M. Miyasaki [Canada] ; Jean A. Saint-Cyr [Canada] ; Yu-Yan W. Poon [Canada] ; William D. Hutchison [Canada] ; Jonathan O. Dostrovsky [Canada] ; Elena Moro [Canada] | Levodopa response in long-term bilateral Subthalamic stimulation for Parkinson's disease |
000679 |
R. B. Postuma [Canada] ; A. J. Espay [Canada] ; C. Zadikoff [Canada] ; O. Suchowersky [Canada] ; W. R. W. Martin [Canada] ; A.-L. Lafontaine [Canada] ; R. Ranawaya [Canada] ; R. Camicioli [Canada] ; A. E. Lang [Canada] | Vitamins and entacapone in levodopa-induced hyperhomocysteinemia : A randomized controlled study |
000683 |
Susan H. Fox [Canada] ; Anthony E. Lang [Canada] ; Jonathan M. Brotchie [Canada] | Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies : Keys to success and roads to failure |
000701 |
Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in Parkinsonian monkeys : Implication of preproenkephalin |
000708 |
Carl Julien [Canada] ; Line Berthiaume [Canada] ; Abdallah Hadj-Tahar [Canada] ; Ali H. Rajput [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] ; Pierre Julien [Canada] ; Frédéric Calon [Canada] | Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys |
000724 |
Zoran Todorovic [Serbie] ; Eleonora Dzoljic [Serbie] ; Ivana Novakovic [Serbie] ; Dusko Mirkovic [Serbie] ; Radan Stojanovic [Serbie] ; Zorica Nesic [Serbie] ; Maja Krajinovic [Canada] ; Milica Prostran [Serbie] ; Vladimir Kostic [Serbie] | Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy |
000725 |
Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of parkinson's disease |
000737 |
Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Claude Rouillard [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] ; Daniel Levesque [Canada] | Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys |
000738 |
Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni] | Development of dyskinesias in a 5-year trial of ropinirole and L-dopa |
000755 |
Vesna Sossi [Canada] ; Raul De La Fuente-Fernandez [Espagne] ; Michael Schulzer [Canada] ; John Adams [Canada] ; Jon Stoessl [Canada] | Age-related differences in levodopa dynamics in Parkinson's : implications for motor complications |
000757 |
Naomi P. Visanji [Canada] ; Mark J. Millan [France] ; Jonathan M. Brotchie [Canada] | Actions at sites other than D3 receptors mediate the effects of BP897 on L-DOPA-induced hyperactivity in monoamine-depleted rats |
000760 |
Monty A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Canada] | Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of parkinson's disease |
000776 |
Kyle G. Melvin [Canada] ; Jon Doan [Canada] ; Sergio M. Pellis [Canada] ; Lesley Brown [Canada] ; Ian Q. Whishaw [Canada] ; Oksana Suchowersky [Canada] | Pallidal deep brain stimulation and L-dopa do not improve qualitative aspects of skilled reaching in parkinson's disease |
000779 |
Jonathan M. Brotchie [Canada] | Nondopaminergic mechanisms in levodopa-induced dyskinesia |
000800 |
Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Arash Rassoulpour [États-Unis] ; Paolo Guidetti [Canada] ; Emanuela Izzo [Italie] ; Robert Schwarcz [États-Unis] ; Paul J. Bedard [Canada] | Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys |
000809 |
Véronique Sgambato-Faure [France] ; Virginie Buggia [France] ; Frangois Gilbert [Canada] ; Daniel Levesque [Canada] ; Alim-Louis Benabid [France] ; Francois Berger [France] | Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-lnduced behavioral sensitization in dyskinetic rats |
000824 |
GUOWEI HUANG [Canada, République populaire de Chine] ; Magdalena Dragan [Canada] ; David Freeman [Canada] ; John X. Wilson [Canada, États-Unis] | Activation of catechol-O-methyltransferase in astrocytes stimulates homocysteine synthesis and export to neurons |
000826 |
Tom H. Johnston [Canada] ; Joohyung Lee [Canada] ; Jordi Gomez-Ramirez [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease |
000838 |
J. E. Nash [Canada] ; P. Ravenscroft [Royaume-Uni] ; S. Mcguire [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; F. S. Menniti [États-Unis] ; J. M. Brotchie [Canada] | The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease |
000847 |
M. A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; P. Ravenscroft [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; M. J. Millan [France] ; J. M. Brotchie [Canada] | Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate |
000861 |
D. J. Doudet [Canada] ; M. L. Cornfeldt [États-Unis] ; C. R. Honey [Canada] ; A. W. Schweikert [États-Unis] ; R. C. Allen [États-Unis] | PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of parkinson's disease |
000868 |
Raul De La Fuente-Fernandez [Canada] ; Vesna Sossi [Canada] ; ZHIGAO HUANG [Canada] ; Sarah Furtado [Canada] ; Jian-Qiang Lu [Canada] ; Donald B. Calne [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada] | Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias |
000869 |
C. Warren Olanow [États-Unis] ; Yves Agid [France] ; Yoshi Mizuno [Japon] ; Alberto Albanese [Italie] ; U. Bonucelli [Italie] ; Philip Damier [France] ; Justo De Yebenes [Espagne] ; Oscar Gershanik [Argentine] ; Mark Guttman [Canada] ; F. Grandas [Espagne] ; Mark Hallett [États-Unis] ; Ole Hornykiewicz [Autriche] ; Peter Jenner [Royaume-Uni] ; R. Katzenschlager [Royaume-Uni] ; William J. Langston [États-Unis] ; Peter Lewitt [États-Unis] ; Eldad Melamed [Israël] ; M. A. Mena [Espagne] ; P. P. Michel [France] ; Catherine Mytilineou [États-Unis] ; Jose A. Obeso [Espagne] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; R. Raisman-Vozari [France] ; Ali H. Rajput [Canada] ; Olivier Rascol [France] ; Christina Sampaio ; Fabrizio Stocchi | Levodopa in the treatment of Parkinson's disease: Current controversies |
000870 |
Y. Kumakura [Danemark] ; E. H. Danielsen [Danemark] ; A. Reilhac [Canada] ; A. Gjedde [Danemark, Canada] ; P. Cumming [Danemark] | Levodopa effect on [18F]fluorodopa influx to brain: normal volunteers and patients with Parkinson's disease |
000871 |
Erwan Bezard [France] ; Michael P. Hill [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Anne Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque |
000873 |
Frédéric Calon [Canada] ; Mehdi Dridi [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Ali H. Rajput [Canada] ; Thérèse Di Paolo [Canada] | Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias |
000874 |
Ronald B. Postuma [Canada] ; Anthony E. Lang [Canada] | Homocysteine and levodopa: Should Parkinson disease patients receive preventative therapy? |
000884 |
Naila Ismayilova [Canada] ; Alan Crossman [Canada] ; Alexei Verkhratsky [Canada] ; Jonathan Brotchie [Canada] | Effects of adenosine A1, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised rats |
000903 |
Ajit Kumar [Canada] ; Sharanpal Mann [Canada] ; Vesna Sossi [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada] ; Michael Schulzer [Canada] ; Chong S. Lee [Canada] | [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease |
000908 |
W. R. Wayne Martin [Canada] ; Marguerite Wieler [Canada] | Treatment of Parkinson's disease |
000910 |
Pierre J. Blanchet [Canada] | The fluctuating Parkinsonian patient: Clinical and pathophysiological aspects |
000917 |
Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias [Canada] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni] | Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study |
000934 |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset |
000937 |
A. Hadj Tahar [Canada] ; R. Grondin [Canada] ; L. Gregoire [Canada] ; F. Calon [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable |
000965 |
Michael Iskedjian [Canada] ; Thomas R. Einarson [Canada] | Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease |
000970 |
Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Paul J. Bedard [Canada] | Chronic treatment with small doses of cabergoline prevents Dopa-induced dyskinesias in Parkinsonian monkeys |
000971 |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications |
000975 |
D. J. Brooks [Royaume-Uni] ; K. A. Frey [États-Unis] ; K. L. Marek [États-Unis] ; D. Cakes [États-Unis] ; D. Paty [Canada] ; R. Prentice [États-Unis] ; C. W. Shults [États-Unis] ; A. J. Stoessl [Canada] | Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease |
000990 |
R. Levy [Canada] ; A. E. Lang [Canada] ; W. D. Hutchison [Canada] ; A. M. Lozano [Canada] ; J. O. Dostrovsky [Canada] | Simultaneous repetitive movements following pallidotomy or subthalamic deep brain stimulation in patients with Parkinson's disease |
000A13 |
Frédéric Calon [Canada] ; Sam Birdi [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias |
000A27 |
G. A. Metz [Canada] ; I. Q. Whishaw [Canada] | Drug-induced rotation intensity in unilateral dopamine-depleted rats is not correlated with end point or qualitative measures of forelimb or hindlimb motor performance |
000A37 |
Nicole Duchesne [Canada] ; Jean-Paul Soucy [Canada] ; Hélène Masson [Canada] ; Sylvain Chouinard [Canada] ; Marc-André Bedard [Canada] | Cognitive deficits and striatal dopaminergic denervation in Parkinson's disease: A single photon emission computed tomography study using 123Iodine-β-CIT in patients on and OFF levodopa |
000A38 |
Azi H. Rajput [Canada] ; Mark E. Fenton [Canada] ; Sam Birdi [Canada] ; Rob Macaulay [Canada] ; David George [Canada] ; Bohdar Rozdilsky [Canada] ; Lee C. Ang [Canada] ; Ambikaipakan Senthilselvan [Canada] ; Oleh Hornykiewicz [Autriche] | Clinical-pathological study of levodopa complications |
000A53 |
Ali H. Rajput [Canada] | The protective role of levodopa in the human substantia nigra |
000A80 |
Richard Camicioli [États-Unis, Canada] ; Eric Lea [États-Unis] ; John G. Nutt [États-Unis] ; Gary Sexton [États-Unis] ; Barry S. Oken [États-Unis] | Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: A pilot study |
000A87 |
M. Guttman [Canada] ; D. Stewart [Canada] ; D. Hussey [Canada] ; A. Wilson [Canada] ; S. Houle [Canada] ; S. Kish [Canada] | Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD |
000B26 |
Oksana Suchowersky [États-Unis, Canada] ; Peter Bailey ; E. Pourcher ; Lynne Bulger ; Giovanni Facciponte | Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD |
000B32 |
Raul De La Fuente-Fernandez [Canada] ; Jian-Qiang Lu [Canada] ; Vesna Sossi [Canada] ; Salma Jivan [Canada] ; Michael Schulzer [Canada] ; James E. Holden [États-Unis] ; Chong S. Lee [Canada] ; Thomas J. Ruth [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada] | Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease : PET evidence of increased dopamine turnover |
000B46 |
D. J. Chong [Canada] ; O. Suchowersky [Canada] ; C. Szumlanski [États-Unis] ; R. M. Weinshilboum [États-Unis] ; R. Brant [Canada] ; N. R. C. Campbell [Canada] | The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's Disease |
000B53 |
ABDALLAH HADJ TAHAR [Canada] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Paul J. Bedard [Canada] | Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys |
000B54 |
A. E. Lang [Canada] ; LANGSTON ; RASCOL ; BROTCHIE ; BENABID ; MELAMED ; BONUCELLI ; OLANOW ; OBESO ; GIMENEZ-ROLDAN ; RAJPUT ; FAHN ; NUTT ; BROOKS ; CHASE | Surgery for levodopa-induced dyskinesias. Discussion |
000B58 |
Erich Mohr [Canada] ; Tilak Mendis [Canada] ; Kathleen Hildebrand [Canada] ; Peter Paul De Deyn [Belgique] | Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial |
000B65 |
M. Filion [Canada] ; OBESO ; BENABID ; OLANOW ; LANG ; HIRSCH ; NUTT | Physiologic basis of dyskinesia. Discussion |
000B81 |
F. Calon [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; P. J. Blanchet [Canada] ; T. T. Di Paolo [Canada] ; P. J. Bedard [Canada] | Molecular basis of levodopa-induced dyskinesias |
000B94 |
C. S. Lee [Canada] ; M. A. Cenci [Suède] ; M. Schulzer [Canada] ; A. Björklund [Suède] | Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease |
000B95 |
J. M. Van Kampen [Canada] ; A. J. Stoessl [Canada] | Effects of oligonucleotide antisense to dopamine D1A receptor messenger RNA in a rodent model of levodopa-induced dyskinesia |
000B97 |
Frédéric Calon [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Pierre J. Blanchet [Canada] ; Marc Morissette [Canada] ; Richard Grondin [Canada] ; Martin Goulet [Canada] ; Jean-Pierre Doucet [Canada] ; George S. Robertson [Canada] ; Eric Nestler [États-Unis] ; Thérèse Di Paolo [Canada] ; Paul J. Bedard [Canada] | Dopamine-receptor stimulation : biobehavioral and biochemical consequences |
000C19 |
D. A. Grimes [Canada] ; A. E. Lang | Treatment of early Parkinson's disease |
000C24 |
Juan Fernandez-Ruiz [États-Unis] ; Doris Doudet [Canada] ; Thomas G. Aigner [États-Unis] | Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys |
000C39 |
D. B. King [Canada] | Parkinson's disease : Levodopa complications |
000C60 |
V. D. Doan [Canada] ; R. Grondin [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada] | Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys |
000C65 |
R. Grondin [Canada] ; V. D. Doan ; L. Gregoire ; P. J. Bedard | D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys |
000C78 |
A. Hadjtahar [Canada] ; P. J. Bedard [Canada] | Comprendre et traiter les dyskinésies induites par la levodopa |
000C81 |
A. H. Rajput [Canada] ; W. Martin [Canada] ; M.-H. Saint-Hilaire [États-Unis] ; E. Dorflinger [États-Unis] ; S. Pedder [États-Unis] | Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon : A double-blind, placebo-controlled, multicenter trial |
000D05 |
J. H. Growdon [États-Unis] ; K. Kieburtz [Canada] ; M. P. Mcdermott [Canada] ; M. Panisset [Canada] ; J. H. Friedman [États-Unis] | Levodopa improves motor function without impairing cognition in mild nondemented Parkinson's disease patients |
000D28 |
D. A. Loeffler [États-Unis] ; P. A. Lewitt [États-Unis] ; P. L. Juneau [États-Unis] ; D. M. Camp [États-Unis] ; A. J. Demaggio [États-Unis] ; P. Milbury [États-Unis] ; W. R. Matson [États-Unis] ; M. P. Rathbone [Canada] | Altered guanosine and guanine concentrations in rabbit striatum following increased dopamine turnover |
000D45 |
A. Destee [France] | Données séméiologiques et principes actuels du traitement médical |
000D50 |
A. H. Rajput [Canada] ; W. Martin [Canada] ; M.-H. Saint-Hilaire [États-Unis] ; E. Dorflinger [États-Unis] ; S. Pedder [États-Unis] | Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial |
000D60 |
C.-T. Lai [Canada] ; P. H. Yu [Canada] | R(-)-deprenyl potentiates dopamine induced cytotoxicity toward catecholaminergic neuroblastoma SH-SY5Y cells |
000D62 |
R. Grondin [Canada] ; P. J. Bedard [Canada] ; D. R. Britton [États-Unis] ; K. Shiosaki [États-Unis] | Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929 : An acute study in parkinsonian levodopa-primed monkeys |
000D91 |
C.-T. Lai [Canada] ; P. H. Yu [Canada] | Dopamine- and L-β-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells : effects of oxidative stress and antioxidative factors |
000D92 |
A. Rajput [États-Unis] ; A. Kishore [Canada] ; B. Snow [Canada] ; C. F. Bolton [Canada] ; A. H. Rajput [Canada] | Dopa-responsive, nonprogressive, juvenile parkinsonism : Report of a case |
000E02 |
D. D. Newman [Canada] ; N. Rajakumar ; B. A. Flumerfelt ; A. J. Stoessl [Canada] | A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease |
000E11 |
P. J. Blanchet [Canada] ; P. Allard [Canada] ; L. Gregoire [Canada] ; F. Tardif [Canada] ; P. J. Bedard [Canada] | Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients |
000E60 |
P. J. Blanchet ; B. Gomez-Mancilla [Canada] ; T. Di Paolo ; P. J. Bedard | Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia ? |
000F12 |
A. H. Rajput [Canada] ; W. R. G. Gibb ; X. H. Zhong ; K. S. Shannak ; S. Kish ; L. G. Chang ; O. Hornykiewicz | Dopa-responsive dystonia : pathological and biochemical observations in a case |
000F45 |
P. Blanchet [Canada] ; P. J. Bedard [Canada] ; D. R. Britton ; J. W. Kebabian | Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys |
001048 |
N. R. C. Campbell ; D. Rankine ; A. E. Goodridge ; B. B. Hasinoff ; M. Kara | Sinemet-ferrous sulphate interaction in patients with Parkinson's disease |
001084 |
W. G. Vincken ; C. M. Darauay ; M. G. Cosio | Reversibility of upper airway obstruction after levodopa therapy in Parkinson's disease |
001146 |
A. E. Lang | Manipulating the dopaminergic system in Parkinson's disease |
001159 |
I. Libman ; M. J. Gawel ; R. J. Riopelle ; S. Bouchard | A comparison of bromocriptine (Parlodel®) and levodopa-carbidopa (Sinemet®) for treatment of "De Novö Parkinson's disease patients |
001178 |
M. Guttman ; P. Seeman ; G. P. Reynolds ; P. Riederer ; K. Jellinger ; W. W. Tourtellotte | Dopamine D2 receptor density remains constant in treated Parkinson's disease |